Ciprofloxacin reduces the stimulation of prostaglandin E_2 output by interleukin-1β in human tendon-derived cells

A. N. Corps, V. A. Curry, R. L. Harrall, D. Dutt, B. L. Hazleman and G. P. Riley

Objective. Fluoroquinolone antibiotics such as ciprofloxacin can induce tendon pathology and have various effects on tendon-derived cells in culture. We are investigating whether ciprofloxacin modifies signalling responses in tendon cells.
Methods. Human Achilles tendon-derived cells were preincubated with or without ciprofloxacin (50 μg/ml) and were then challenged with interleukin-1β (IL-1β, 1 ng/ml) for up to 48 h. Prostaglandin E_2 (PGE$_2$) output was assayed by ELISA. The expression of cyclooxygenase-2 (COX-2) was examined by Western blotting.
Results. IL-1β stimulated a substantial and prolonged increase in the output of PGE$_2$. Preincubation with ciprofloxacin reduced IL-1β-induced PGE$_2$ output at all times tested; the reduction at 48 h was 69% (99% confidence interval 59–79%; 15 experiments). Norfloxacin and ofloxacin also reduced PGE$_2$ output. However, ciprofloxacin did not affect the induction of COX-2 by IL-1β, measured at 4 or 48 h.
Conclusions. Ciprofloxacin reduces IL-1β-induced PGE$_2$ output in tendon-derived cells. The reduction in PGE$_2$ output could modulate various cellular activities of IL-1β, and may be implicated in fluoroquinolone-induced tendinopathy.

KEY WORDS: Tendon, Fluoroquinolone, Prostaglandin, Interleukin, Cyclooxygenase-2.

The fluoroquinolone antibiotics (ciprofloxacin, norfloxacin, ofloxacin, pefloxacin and others) have been used to treat a wide range of infections. Side-effects have been reported in the gastrointestinal tract and central nervous system [1], and additionally in cartilage and tendon [1, 2]. Tendon pain and/or rupture has been reported in a small proportion of patients in a number of clinical studies, Achilles tendons being the principal tendons affected [2]. Inflammation of the paratenon, disorganization of the extracellular matrix and degenerative changes in tendon cells have been noted in studies of fluoroquinolone-treated animals [3–5].

While the principal target of fluoroquinolone antibacterial activity is the enzyme DNA gyrase [6], several effects of fluoroquinolones on mammalian tissues and cells have been reported. Mitochondrial structure and function may be compromised [5, 7–10], which may underlie the cytotoxic and/or apoptotic effects occurring in various cell types treated with high concentrations of fluoroquinolones [8–10]. A non-cytotoxic reduction of tendon cell proliferation has also been reported [11]. Fluoroquinolones may modulate the expression of inflammatory cytokines [12–15], some of these effects being correlated with changes in transcription factor induction [13, 15]. Changes in the expression of extracellular matrix proteins have also been observed in organ- and cell-culture systems derived from cartilage and tendon [7, 11, 16], and the expression of proteinases was shown to be modulated by ciprofloxacin in canine [11] and human tendon-derived cells [17].

We found that ciprofloxacin potentiated IL-1β-stimulated expression of matrix metalloproteinase (MMP)-3 (mRNA and secreted proenzyme) in human Achilles tendon-derived cells [17]. Increased expression of MMP-1 mRNA was also observed [17]. These results prompted us to investigate whether ciprofloxacin modulates IL-1β-induced signalling responses in tendon-derived cells.

Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, UK.

Correspondence to: A. N. Corps, Rheumatology Research Unit, Box 194, Unit E6, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK.

Materials and methods

Materials

Ciprofloxacin was obtained from ICN (Basingstoke, UK), and was freshly dissolved at 10 mg/ml in 0.1 M HCl, except for some early experiments in which ciprofloxacin was dissolved in DMSO (as described in [17]). IL-1β was a gift from Glaxo Wellcome (Stevenage, UK) and aliquots (1 μg/ml) were stored at –70°C. Dulbecco's modified Eagle's medium (DMEM), fetal calf serum (FCS) and antibiotics were obtained from Invitrogen (Paisley, UK). Primary antibodies against β-actin and cyclooxygenase-2 (COX-2) were from Sigma (Poole, UK) and Santa Cruz (Insight Biotechnology, Wembley, UK) respectively. Secondary antibodies and detection reagent (CDP-Star) were by Dako (Ely, UK) and Tropix (Roche Diagnostics, Lewes, UK).

Cell isolation and incubation

Tendon specimens were obtained from tissue discarded during surgery for chronic Achilles tendinopathy, with informed patient consent and local ethical committee approval. Cells isolated by outgrowth from separate tendon explants were maintained and passaged in DMEM containing 10% (v/v) FCS, penicillin, streptomycin and 25 mM HEPES, and were used between passages 4 and 10. Cells were seeded at 10^5 cells/well in six-well plates and were incubated for 3 days before the experiment. They were rinsed with 2 ml of medium containing 10% FCS or in serum-free medium containing insulin, transferrin and selenium, and were then given 2 ml of the same medium with or without ciprofloxacin (50 μg/ml). After 48 h, the cells were again rinsed and given fresh medium containing ciprofloxacin and/or IL-1β (1 ng/ml). Control cultures had equivalent additions of HCl or DMSO as appropriate. After further incubation up to 48 h, the supernatant medium was removed and stored at –20°C, and the cells were extracted for Western blotting.

Western blotting

Cells were rinsed with ice-cold balanced salts solution, and were lysed for 15 min on ice using 300 μl of extraction buffer [10 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM Na$_3$VO$_4$, 50 mM NaF, 20 mM Na$_4$P$_2$O$_7$, 1 mM PMSF (phenylmethylsulphonyl fluoride), 1 μg/ml leupeptin, 1 μg/ml aprotinin, 1% NP-40]. The extracts were centrifuged to remove debris (2 min at 12 000 g at 4°C) and were stored at –70°C. Aliquots (20 μl) were subjected to sodium dodecyl sulphate–polyacrylamide gel electrophoresis under reducing conditions, using a 10% (w/v) polyacrylamide resolving gel with a 4.5% (w/v) stacking gel. The proteins were electroblotted onto PVDF (polyvinylidene fluoride) membranes. These were blocked, incubated with primary antibodies, washed, incubated with secondary antibodies, washed and developed using standard protocols.

Prostaglandin E$_2$ assay

Samples of cell supernatants were assayed in duplicate using a colorimetric competitive enzyme-linked immunosorbent assay (ELISA) for prostaglandin (PG) E$_2$ (R&D Systems, Abingdon, UK) according to the supplier's instructions. All dilutions of standards and samples were performed using culture medium. The effective range of the assay was 39–5000 pg/ml. For the analysis of early time-points, a high-sensitivity PGE$_2$ ELISA from the same supplier was used: the effective range of this assay was 8–1000 pg/ml. The addition of ciprofloxacin, DMSO or IL-1β at concentrations equivalent to those present in the cell supernatants did not affect the values obtained for PGE$_2$ standards.

Replication and presentation of data

The principal effect observed (the decrease in IL-1β-stimulated PGE$_2$ output) was obtained in at least two experiments with cells isolated from each of five separate tendons. Because PGE$_2$ output varied between experiments, the results in each experiment were generally normalized to the value for cells treated with IL-1β after control preincubation, defined as 100%. Significant differences from the 100% value were determined from the 95 or 99% confidence intervals (CI) of the different treatments ($P < 0.05$ and $P < 0.01$ respectively).

Results

The basal output of PGE$_2$ by tendon-derived cells was close to or below the minimum detection limit of the assay (40 pg/ml, corresponding to about 80 pg/10^5 cells in 48 h). In serum-free medium, PGE$_2$ output from IL-1β-stimulated cells remained close to the minimum detection limit (the maximum observed being 135 pg/ml in 48 h, in one of five separate experiments) and it was not possible to deduce a consistent pattern of effect of ciprofloxacin (data not shown). In contrast, when cells were incubated in medium containing 10% FCS, IL-1β stimulated a substantial, rapid and prolonged increase in PGE$_2$ output (Fig. 1). There was considerable variation between experiments in the magnitude of IL-1β-stimulated PGE$_2$ output, ranging between 1.2 and 65 ng/ml after 48 h (Fig. 1A; mean $\pm$ S.E.M., 19 $\pm$ 5 ng/ml; $n = 15$). Irrespective of the magnitude of stimulation, pretreatment of the cells with ciprofloxacin reduced PGE$_2$ output in IL-1β-stimulated cells (Fig. 1A). The reduction was 69% at 48 h compared with cells given control pretreatment (99% CI 59–79; $n = 15$), and was evident from early time-points (Fig. 1B), being 82% after 4 h and 68% after 8 h (95% CI 64–100 and 40–96 respectively; $n = 3$). Pretreatment with the related fluoroquinolones norfloxacin and ofloxacin also reduced the stimulation of PGE$_2$ output, by 55 and 46% over 48 h (99% CI 26–82 and 19–71 respectively; $n = 3$), but the non-fluorinated quinolone nalidixic acid was more variable in effect, giving 77% inhibition in one of three experiments but no significant effect overall (data not shown).

Because the stimulated production of PGE$_2$ frequently involves increased expression of the PGH synthase enzyme COX-2 [18], we examined the levels of COX-2 in tendon cells stimulated with IL-1β after pretreatment with and without ciprofloxacin. Control cells showed little or no immunodetectable COX-2 protein (Fig. 2). Substantial induction of COX-2 expression was stimulated by IL-1β within 4 h and was maintained up to 48 h (Fig. 2). Ciprofloxacin did not affect either the basal or the IL-1β-stimulated expression of COX-2 at 4 or 48 h (Fig. 2).

FIG. 1. PGE$_2$ output by human tendon-derived cells. Cells were pretreated for 48 h with or without ciprofloxacin, and were then incubated with ciprofloxacin (cip) and/or IL-1β for between 4 and 48 h. Cell supernatants were analysed by ELISA for PGE$_2$. (A) PGE$_2$ output over 48 h by IL-1β-treated cells after control pretreatment or pretreatment with ciprofloxacin. The output from cells incubated without IL-1β was less than 0.1 ng/ml, and is not shown. Results from 15 separate experiments. (B) Early time-course showing cells treated with IL-1β (squares) or without IL-1β (circles), after control pretreatment (open symbols) or pretreatment with ciprofloxacin (filled symbols). Mean ± S.E.M. from three experiments.

Discussion

Fluoroquinolones have been reported to have a range of effects on mammalian cells, both *in vivo* and *in vitro*, ranging from gross ultrastructural perturbation of organelles such as mitochondria to specific and contrasting changes in gene expression (see Introduction). We are investigating whether fluoroquinolones affect signalling responses in human tendon cells.

As in other cell-types [19, 20], IL-1β induced a prolonged increase in COX-2 expression and PGE$_2$ output in human tendon fibroblasts (Figs 1 and 2).


FIG. 2. Expression of cyclooxygenase-2 in human tendon-derived cells. Cells were pretreated for 48 h with or without ciprofloxacin, and were then incubated with ciprofloxacin (cip) and/or IL-1β for a further 4 or 48 h. Cell extracts were analysed by Western blotting using antibodies specific for COX-2 (upper panels) or β-actin (lower panels) as the loading control. Similar results were obtained in two additional experiments.

Ciprofloxacin did not affect the expression of COX-2 after treatment with IL-1β (Fig. 2), or the IL-1β-induced phosphorylation of the signalling kinases p54 JNK/ SAPK and p38MAPK (data not shown). These results established that preincubation with ciprofloxacin did not generally compromise or enhance signal transduction at the IL-1 receptor. However, ciprofloxacin (and other fluoroquinolones) reduced the output of PGE$_2$ induced by IL-1β in tendon cells by up to 90% (Fig. 1). This reduction in PGE$_2$ output was similar in magnitude to that induced by low concentrations of the COX-2 inhibitors indomethacin and NS398 (data not shown). It is possible that ciprofloxacin might also act as a COX-2 inhibitor; alternatively, the reduction in stimulated PGE$_2$ output could be due to reduced mobilization of arachidonic acid (the precursor for PG synthesis), by inhibition of phospholipase activation or activity [18]. We are not aware of any data currently available that would distinguish between these possibilities. In contrast to our data for PGE$_2$, an increase in PGI$_2$ was reported for endothelial cells treated with fluoroquinolones [9]. This may indicate either that the effect of fluoroquinolones on prostanoid synthesis is cell-type-specific or that it occurs downstream of COX-2 [18].

A reduction in PGE$_2$ output provides a mechanism by which fluoroquinolones might affect a variety of cellular responses. For example, the use of indomethacin to inhibit PG production, thereby reducing feedback inhibition, can enhance the IL-1-induced expression of matrix-related genes, including MMPs, in some cell types [21, 22]. A reduction in feedback inhibition, via reduced PGE$_2$ output, thus seemed to be a possible explanation for our previous observation that ciprofloxacin enhanced MMP expression induced by IL-1β in tendon cells [17]. However, we found that indomethacin and NS398 neither mimicked nor blocked the enhancement of MMP expression by ciprofloxacin in these cells (data not shown), indicating that additional mechanisms must underlie this effect.

The role of PGs in tendon physiology and pathology is uncertain. Although non-steroidal anti-inflammatory

drugs are commonly used in the treatment of tendinopathies, most histopathological studies have demonstrated the non-inflammatory (degenerative) nature of the condition, at least at the end stage of the disease [23, 24]. Furthermore, no significant increase in PG levels was detected in the peritendinous fluid in various tendinopathies [25, 26]. On the other hand, levels of PGE_2 were increased in the peritendinous space in the recovery period after strenuous exercise and there was evidence for increased collagen degradation [27]. Similarly, tendon cells exposed to cyclic strain *in vitro* showed increased expression of PGE_2, and increased DNA and protein synthesis, compared with unstretched control cells [28]. Indomethacin inhibited PGE_2 output and DNA synthesis in stretched cells, but increased levels of protein synthesis [29]. These data are consistent with the hypothesis that PGs are implicated in the adaptive response of the tendon, acting to modulate the remodelling of the extracellular matrix, and interference with this response could contribute to the tendinopathy induced by ciprofloxacin. However, the levels of PGs in ciprofloxacin-induced human tendinopathies have not yet been reported. It therefore remains to be determined whether a reduction in PG synthesis is one of the factors contributing to ciprofloxacin-induced tendinopathy.

Acknowledgements

Conflict of interest

The authors declare that there is no conflict of interest with respect to the work described in this article.

References

1. De Sarro A, De Sarro G. Adverse reactions to fluoroquinolones: an overview on mechanistic aspects. Curr Med Chem 2001;8:371–84.
2. Pierfitte C, Royer RJ. Tendon disorders with fluoroquinolones. Therapie 1996;51:419–20.
3. Kato M, Takada S, Kashida Y, Nomura M. Histological examination on Achilles tendon lesions induced by quinolone antibacterial agents in juvenile rats. Toxicol Pathol 1995;23:385–92.
4. Kashida Y, Kato M. Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds. Antimicrob Agents Chemother 1997;41:2389–93.
5. Shakibaei M, Stahlmann R. Ultrastructure of Achilles tendon from rats after treatment with fleroxacin. Arch Toxicol 2001;75:97–102.
6. Fisher LM, Lawrence JM, Josty IC, Hopewell R, Margerrison EE, Cullen ME. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance. Am J Med 1989;87:2S–8S.
7. Kato M, Takada S, Ogawara S, Takayama S. Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions *in vivo*. Antimicrob Agents Chemother 1995;39:1979–83.
8. Bernard-Beaubois K, Hecquet C, Hayem G, Rat P, Adolphe M. *In vitro* study of cytotoxicity of quinolones on rabbit tenocytes. Cell Biol Toxicol 1998;14:283–92.
9. Vorbach H, Weigel G, Robibaro B *et al*. Endothelial cell compatibility of fluoroquinolone solutions for intra-venous use. Int J Clin Pharmacol Ther 1997;35:235–8.
10. Herold C, Ocker M, Ganslmayer M, Gerauer H, Hahn EG, Schuppan D. Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer 2002;86:443–8.
11. Williams RJ, Attia E, Wickiewicz TL, Hannafin JA. The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast metabolism. Am J Sports Med 2000;28:364–9.
12. Stunkel KG, Hewlett G, Zeiler HJ. Ciprofloxacin enhances T cell function by modulating interleukin activities. Clin Exp Immunol 1991;86:525–31.
13. Riesbeck K, Forsgren A, Henriksson A, Bredberg A. Ciprofloxacin induces an immunomodulatory stress response in human T lymphocytes. Antimicrob Agents Chemother 1998;42:1923–30.
14. Yoshimura T, Kurita C, Usami E *et al*. Immunomodulatory action of levofloxacin on cytokine production by human peripheral blood mononuclear cells. Chemotherapy 1996;42:459–64.
15. Galley HF, Dhillon JK, Paterson RL, Webster NR. Effect of ciprofloxacin on the activation of the transcription factors nuclear factor kappaB, activator protein-1 and nuclear factor-interleukin-6, and interleukin-6 and interleukin-8 mRNA expression in a human endothelial cell line. Clin Sci 2000;99:405–10.
16. Burkhardt JE, Hill MA, Lamar CH, Smith GN Jr, Carlton WW. Effects of difloxacin on the metabolism of glycosaminoglycans and collagen in organ cultures of articular cartilage. Fundam Appl Toxicol 1993;20:257–63.
17. Corps AN, Harrall RL, Curry VA, Fenwick SA, Hazleman BL, Riley GP. Ciprofloxacin enhances the stimulation of matrix metalloproteinase 3 expression by interleukin-1beta in human tendon-derived cells. A potential mechanism of fluoroquinolone-induced tendinopathy. Arthritis Rheum 2002;46:3034–40.
18. Smith WL, Marnett LJ, DeWitt DL. Prostaglandin and thromboxane biosynthesis. In: Taylor CW, ed. Intracellular messengers. Oxford: Pergamon Press, 1993:101–36.
19. Molina-Holgado E, Ortiz S, Molina-Holgado F, Guaza C. Induction of COX-2 and PGE(2) biosynthesis by IL-1beta is mediated by PKC and mitogen-activated protein kinases in murine astrocytes. Br J Pharmacol 2000;131:152–9.
20. Faour WH, He Y, Wen He Q *et al*. Prostaglandin E(2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J Biol Chem 2001;276:31720–31.
21. Case JP, Lafyatis R, Kumkumian GK, Remmers EF, Wilder RL. IL-1 regulation of transin/stromelysin transcription in rheumatoid synovial fibroblasts appears to involve two antagonistic transduction pathways, an inhibitory, prostaglandin-dependent pathway mediated by cAMP, and a stimulatory, protein kinase C-dependent pathway. J Immunol 1990;145:3755–61.

22. Lin SK, Wang CC, Huang S *et al.* Induction of dental pulp fibroblast matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 gene expression by interleukin-1alpha and tumor necrosis factor-alpha through a prostaglandin-dependent pathway. J Endod 2001;27:185–9.

23. Riley GP, Goddard MJ, Hazleman BL. Histopathological assessment and pathological significance of matrix degeneration in supraspinatus tendons. Rheumatology 2001; 40:229–30.

24. Khan KM, Cook JL, Kannus P, Maffulli N, Bonar F. Time to abandon the 'tendinitis' myth. Br Med J 2002;324:626–7.

25. Alfredson H, Thorsen K, Lorentzon R. *In situ* microdialysis in tendon tissue: high levels of glutamate, but not prostaglandin E2 in chronic Achilles tendon pain. Knee Surg Sports Traumatol Arthrosc 1999;7:378–81.

26. Alfredson H, Forsgren S, Thorsen K, Lorentzon R. *In vivo* microdialysis and immunohistochemical analysis of tendon tissue demonstrated high amounts of free glutamate NMDAR1 receptors, but no signs of inflammation, in Jumper's knee. J Orthop Res 2001;19:881–6.

27. Langberg H, Skovgaard D, Petersen LJ, Bulow J, Kjaer M. Type I collagen synthesis and degradation in peritendinous tissue after exercise determined by microdialysis in humans. J Physiol 1999;521:299–306.

28. Almekinders LC, Banes AJ, Ballenger CA. Effects of repetitive motion on human fibroblasts. Med Sci Sports Exerc 1993;25:603–7.

29. Almekinders LC, Banes AJ, Bracey LW. An *in vitro* investigation of repetitive motion and nonsteroidal anti-inflammatory medication on human tendon fibroblasts. Am J Sports Med 1995;23:119–23.